Selecting Endpoints for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT consensus from the IOIBD.

Date publication

janvier 2021

Journal

Gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Le Berre C, Peyrin-Biroulet L,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33421515

Résumé

Inflammatory bowel diseases (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), are chronic and disabling disorders. Prospective disease-modification trials to prevent disease progression are eagerly awaited. However, disease progression is not clearly defined. The objective of the Selecting EndPoInts foR Disease-ModIfication Trials (SPIRIT) initiative was to achieve international expert consensus on the endpoints to be used in future IBD-disease modification trials.

Mots clés

Crohn’s disease, Disease severity, disease progression, ulcerative colitis

Référence

Gastroenterology. 2021 Jan 6;: